End-stage Renal Disease Market Size (2024 - 2029)

End Stage Renal Disease Market Analysis

The end-stage renal disease market is expected to witness a CAGR of around 10% during the forecast period.

The COVID-19 pandemic forced unprecedented changes in the daily life of people. Many patients were under lockdown during this time, and the nephrology community was forced to adapt quickly to this new reality. Patients on dialysis were at high risk of COVID-19 exposure due to the widespread use of public transportation and densely packed clinical spaces. For instance, according to an article published by Karger in June 2022, chronic hemodialysis (HD) patients were considered at high risk of severe COVID-19 with an increased risk of death, and the constraints during the pandemic had an impact on the dialysis delivery to COVID-free hemodialysis patients. Thus the COVID-19 pandemic had a significant effect on the current market initially. However, post-pandemic, the market studied is expected to grow significantly during the forecast period.

The end-stage renal disease market is driven by the increasing number of patients suffering from chronic kidney disease. According to the article published by PubMed Central in April 2022, approximately 10% of the global population suffers from chronic kidney disease, and millions die each year. According to the same article, the rate of patients with chronic kidney disease is increasing.

Another factor is the introduction of technologically advanced products, like low-maintenance dialysis equipment and artificial kidney. In March 2021, Baxter International Inc. announced the United States FDA clearance of its next-generation Artificial Kidney 98 dialysis machine, designed to be a portable and easy-to-use system to administer hemodialysis (HD) treatments. This indicated that companies are taking initiatives to establish a strong footprint and launch technologically advanced products in the market.

Additionally, there is a higher prevalence rate for diabetes, which leads to cause end-stage renal disease in the long run, which may drive the market growth. According to the International Diabetes Federation, in 2021, around 537 million adults (20-79 years) were living with diabetes. The total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 by 2045. Diabetes is one of the leading causes of kidney failure, which is likely to drive the market's growth over the forecast period.

Therefore, owing to the factors mentioned above, such as the rising prevalence of diabetes and the introduction of technologically advanced products, the market studied is anticipated to witness growth over the analysis period. However, the delay in diagnosing chronic kidney disease may restrain the market growth over the forecast period.

End Stage Renal Disease Industry Segmentation

End-stage renal failure, also known as an end-stage renal disease (ESRD), is the final, permanent stage of chronic kidney disease, where kidneys can no longer function independently. 

The End-stage Renal Disease Market is Segmented by Treatment (Kidney Transplantation and Dialysis), Diagnosis (Blood Test, Urine Test, Imaging Test, and Other Diagnoses), and Geography (North America (United States, Canada, and Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, and Rest of Middle East and Africa), and South America Brazil, Argentina, and Rest of South America)). The report offers value (in USD million) for the above segments.